Disruption of gene expression and induction of apoptosis in prostate cancer cells by a DNA-damaging agent tethered to an androgen receptor ligand

Chemistry and Biology

Volumn 12, Issue 7, 2005, Pages 779-787

  Marquis, John C ^a   Hillier, Shawn M ^a   Dinaut, A Nicole ^a   Rodrigues, Denise ^a   Mitra, Kaushik ^a   Essigmann, John M ^a   Croy, Robert G ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTRADIOL; INTERCALATING AGENT; LIGAND; STEROID;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CHEMISTRY; DNA ADDUCT; DNA DAMAGE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; APOPTOSIS; DNA ADDUCTS; DNA DAMAGE; ESTRADIOL; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERCALATING AGENTS; LIGANDS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROIDS, CHLORINATED; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 22544462553     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2005.05.009     Document Type: Article

References (43)

1. V.T. DeVita Principles of cancer management: chemotherapy V.T. DeVita S. Hellman S.A. Rosenberg Cancer: Principles and Practice of Oncology 1997 Lippincott-Raven New York 333 348
2. L.H. Hurley DNA and its associated processes as targets for cancer therapy Nat. Rev. Cancer 2 2002 188 200
3. J.R. Masters, and B. Koberle Curing metastatic cancer: lessons from testicular germ-cell tumours Nat. Rev. Cancer 3 2003 517 525
4. S.M. Rink, K.J. Yarema, M.S. Solomon, L.A. Paige, B.M. Tadayoni-Rebek, J.M. Essigmann, and R.G. Croy Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor Proc. Natl. Acad. Sci. USA 93 1996 15063 15068
5. K. Mitra, J.C. Marquis, S.M. Hillier, P.T. Rye, B. Zayas, A.S. Lee, J.M. Essigmann, and R.G. Croy A rationally designed genotoxin that selectively destroys estrogen receptor-positive breast cancer cells J. Am. Chem. Soc. 124 2002 1862 1863
6. U. Sharma, J.C. Marquis, D.A. Nicole, S.M. Hillier, B. Fedeles, P.T. Rye, J.M. Essigmann, and R.G. Croy Design, synthesis, and evaluation of estradiol-linked genotoxicants as anti-cancer agents Bioorg. Med. Chem. Lett. 14 2004 3829 3833
7. C.A. Heinlein, and C. Chang Androgen receptor in prostate cancer Endocr. Rev. 25 2004 276 308
8. J.A. Ruizeveld de Winter, P.J. Janssen, H.M. Sleddens, M.C. Verleun-Mooijman, J. Trapman, A.O. Brinkmann, A.B. Santerse, F.H. Schroder, and T.H. van der Kwast Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer Am. J. Pathol. 144 1994 735 746
9. G. Buchanan, R.A. Irvine, G.A. Coetzee, and W.D. Tilley Contribution of the androgen receptor to prostate cancer predisposition and progression Cancer Metastasis Rev. 20 2001 207 223
10. C.A. Heinlein, and C. Chang Androgen receptor (AR) coregulators: an overview Endocr. Rev. 23 2002 175 200
11. U. Fuhrmann, H. Hess-Stumpp, A. Cleve, G. Neef, W. Schwede, J. Hoffmann, K.H. Fritzemeier, and K. Chwalisz Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist J. Med. Chem. 43 2000 5010 5016
12. E. Napolitano, R. Fiaschi, and R.N. Hanson Epoxidation of estra-5(10),9(11)-dien derivatives; a convenient synthesis of 11β-vinylestrone acetate Gazz. Chim. Ital. 120 1990 323 326
13. G. Teutsch, and A. Bêlanger Regio and stereospecific synthesis of 11β substituted norsteroids Tetrahedron Lett. 22 1979 2051 2054
14. X.Y. Zhao, B. Boyle, A.V. Krishnan, N.M. Navone, D.M. Peehl, and D. Feldman Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a J. Urol. 162 1999 2192 2199
15. L.F. Povirk, and D.E. Shuker DNA damage and mutagenesis induced by nitrogen mustards Mutat. Res. 318 1994 205 226
16. A. Chan, R. Reiter, S. Wiese, G. Fertig, and R. Gold Plasma membrane phospholipid asymmetry precedes DNA fragmentation in different apoptotic cell models Histochem. Cell Biol. 110 1998 553 558
17. W. Gorczyca, K. Bigman, A. Mittelman, T. Ahmed, J. Gong, M.R. Melamed, and Z. Darzynkiewicz Induction of DNA strand breaks associated with apoptosis during treatment of leukemias Leukemia 7 1993 659 670
18. S.H. Kaufmann, S. Desnoyers, Y. Ottaviano, N.E. Davidson, and G.G. Poirier Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis Cancer Res. 53 1993 3976 3985
19. A.C. Carrano, E. Eytan, A. Hershko, and M. Pagano SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 Nat. Cell Biol. 1 1999 193 199
20. L. Lu, H. Schulz, and D.A. Wolf The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells BMC Cell Biol. 3 2002 22
21. H.P. Brix, M.R. Berger, M.R. Schneider, W.C. Tang, and G. Eisenbrand Androgen-linked alkylating agents: biological activity in methylnitrosourea- induced rat mammary carcinoma J. Cancer Res. Clin. Oncol. 116 1990 538 549
22. G. Eisenbrand, M.R. Berger, H.P. Brix, J.E. Fischer, K. Muhlbauer, M.R. Nowrousian, M. Przybilski, M.R. Schneider, W. Stahl, and W. Tang Nitrosoureas. Modes of action and perspectives in the use of hormone receptor affinity carrier molecules Acta Oncol. 28 1989 203 211
23. N. Knebel, and E. von Angerer Platinum complexes with binding affinity for the estrogen receptor J. Med. Chem. 31 1988 1675 1679
24. B. Fredholm, K. Gunnarsson, G. Jensen, and J. Muntzing Mammary tumour inhibition and subacute toxicity in rats of prednimustine and of its molecular components chlorambucil and prednisolone Acta Pharmacol. Toxicol. (Copenh.) 42 1978 159 163
25. T. Kubota, J. Koh, Y. Yamada, S. Oka, K. Enomoto, K. Ishibiki, O. Abe, O. Masui, and K. Asano Mode of action of estra-1,3,5(10)-triene-3,17 beta-diol 3-benzoate 17-[4-(4-bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy)acet ate) on human breast carcinoma xenografts in nude mice Jpn. J. Cancer Res. 79 1988 1224 1229
26. J.S. Sack, K.F. Kish, C. Wang, R.M. Attar, S.E. Kiefer, Y. An, G.Y. Wu, J.E. Scheffler, M.E. Salvati, and S.R. Krystek Jr. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone Proc. Natl. Acad. Sci. USA 98 2001 4904 4909
27. C.A. Berrevoets, A. Umar, and A.O. Brinkmann Antiandrogens: selective androgen receptor modulators Mol. Cell. Endocrinol. 198 2002 97 103
28. J. Veldscholte, C.A. Berrevoets, C. Ris-Stalpers, G.G. Kuiper, G. Jenster, J. Trapman, A.O. Brinkmann, and E. Mulder The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens J. Steroid Biochem. Mol. Biol. 41 1992 665 669
29. S. McDonald, L. Brive, D.B. Agus, H.I. Scher, and K.R. Ely Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors Cancer Res. 60 2000 2317 2322
30. M.E. Taplin, G.J. Bubley, Y.J. Ko, E.J. Small, M. Upton, B. Rajeshkumar, and S.P. Balk Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist Cancer Res. 59 1999 2511 2515
31. C.J. Sherr, and J.M. Roberts Inhibitors of mammalian G1 cyclin-dependent kinases Genes Dev. 9 1995 1149 1163
32. I.Y. Kim, J.H. Kim, D.J. Zelner, H.J. Ahn, J.A. Sensibar, and C. Lee Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP Endocrinology 137 1996 991 999
33. C. Lee, D.M. Sutkowski, J.A. Sensibar, D. Zelner, I. Kim, I. Amsel, N. Shaw, G.S. Prins, and J.M. Kozlowski Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone Endocrinology 136 1995 796 803
34. J. Tsihlias, W. Zhang, N. Bhattacharya, M. Flanagan, L. Klotz, and J. Slingerland Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells Oncogene 19 2000 670 679
35. C. Spruck, H. Strohmaier, M. Watson, A.P. Smith, A. Ryan, T.W. Krek, and S.I. Reed A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1 Mol. Cell 7 2001 639 650
36. D. Ganoth, G. Bornstein, T.K. Ko, B. Larsen, M. Tyers, M. Pagano, and A. Hershko The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27 Nat. Cell Biol. 3 2001 321 324
37. T. Bashir, N.V. Dorrello, V. Amador, D. Guardavaccaro, and M. Pagano Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase Nature 428 2004 190 193
38. T. Sudo, Y. Ota, S. Kotani, M. Nakao, Y. Takami, S. Takeda, and H. Saya Activation of Cdh1-dependent APC is required for G1 cell cycle arrest and DNA damage-induced G2 checkpoint in vertebrate cells EMBO J. 20 2001 6499 6508
39. A.L. Gartel, and A.L. Tyner The role of the cyclin-dependent kinase inhibitor p21 in apoptosis Mol. Cancer Ther. 1 2002 639 649
40. W.B. Isaacs, B.S. Carter, and C.M. Ewing Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles Cancer Res. 51 1991 4716 4720
41. W.S. el-Deiry, T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein WAF1, a potential mediator of p53 tumor suppression Cell 75 1993 817 825
42. L.A. Martinez, J. Yang, E.S. Vazquez, M.C. Rodriguez-Vargas, M. Olive, J.T. Hsieh, C.J. Logothetis, and N.M. Navone p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells Carcinogenesis 23 2002 1289 1296
43. S. Waga, and B. Stillman Cyclin-dependent kinase inhibitor p21 modulates the DNA primer-template recognition complex Mol. Cell. Biol. 18 1998 4177 4187